Skip to main content

Eovist FDA Approval History

FDA Approved: Yes (First approved July 3, 2008)
Brand name: Eovist
Generic name: gadoxetate disodium
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Diagnosis and Investigation

Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Development timeline for Eovist

Jul  8, 2008Approval FDA Approves Eovist to Detect and Characterize Focal Liver Lesions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.